"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Accelerated Approval for Nivolumab (Opdivo) for treatment of patients with locally advanced or metastatic urothelial carcinoma

FDA Accelerated Approval for Nivolumab (Opdivo) for treatment of patients with locally advanced or metastatic urothelial carcinoma

28 Feb 2017 9:52 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approved to nivolumab (Opdivo) for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months or neoadjuvant or adjuvant treatment with a platinum containing chemotherapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software